Brief: Vigil Neuroscience Receives Positive Opinion From European Medicines Agency On Orphan Drug Designation For VGL101 For The Treatment Of ALSP
26/09/2023 12:24
Sept 26 (Reuters) - Vigil Neuroscience Inc VIGL.O :
* VIGIL NEUROSCIENCE RECEIVES POSITIVE OPINION FROM EUROPEAN
MEDICINES AGENCY ON ORPHAN DRUG DESIGNATION FOR VGL101 FOR THE
TREATMENT OF ALSP
* VIGIL NEUROSCIENCE RECEIVES POSITIVE OPINION FROM EUROPEAN
MEDICINES AGENCY ON ORPHAN DRUG DESIGNATION FOR VGL101 FOR THE
TREATMENT OF ALSP
* VIGIL NEUROSCIENCE INC - CURRENTLY EVALUATING VGL101 IN A
PHASE
2 PROOF-OF-CONCEPT TRIAL IN PATIENTS WITH ALSP
Source text for Eikon: ID:nGNX4zpF7f
Further company coverage: VIGL.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Vigil Neuroscience
See all newsVigil Neuroscience Inc reports results for the quarter ended June 30 - Earnings Summary
Vigil Neuroscience Inc expected to post a loss of 42 cents a share - Earnings Preview
Brief: Vigil Neuroscience Provides Update on Iluzanebart Phase 2 IGNITE Trial in ALSP
U.S. RESEARCH ROUNDUP-Ralph Lauren, Vigil Neuroscience, Workday
Deals of the day-Mergers and acquisitions